Event > Conference >
SLAS Europe 2023
This year’s conference and exhibition will feature four important tracks focused on life sciences and their global impact: Biology Unveiled, Frontiers in Technology, Shaping the Future of Therapeutics and Bio-Entrepreneurship in Europe.
Will you be there too?
Head to our exhibition stand – #324
Our dedicated team of creative problem solvers will be available to answer questions and share over a decade of organ-on-a-chip (OOC) expertise with you!
We look forward to meeting you to discuss how our PhysioMimix™ suite of hardware, consumables, assay protocols and services can help to improve the predictivity of your drug discovery workflows and address workflow limitations – such as modeling the immune system in vitro and testing the safety of new modality drugs with human specific modes of action.
Get familiar with our predictive human models and learn more about their proven track record for delivering clinically translatable results, plus meet the new game-changing product in our PhysioMimix OOC range of microphysiological systems, the PhysioMimix Single-organ Higher Throughput (HT) System and associated Multi-chip Liver-48 plate.
Developing microfluidic systems for biochemical and cell based assays
Microfluidics has long offered the promise of smaller, more efficient and more biologically relevant assay systems. However, this has proven challenging due to the behavior of liquids at microliter volumes, bubbles and scale up for manufacturing. Microfluidic systems often also include other components such as environmental control units, optics and/or motion control devices.
Managing all of these elements using iterative design and prototyping can play a key role in successful project delivery. Use of low cost off the shelf mechanical products (e.g., peristaltic and syringe pumps, solenoid valves, programmable logic controllers) coupled with an ability to write basic code gives scientists and engineers the ability to rapidly prototype without the need for large cost overheads.
There is a large amount of, often free, support across variety on topics on many online platforms which make these technologies accessible to everyone. This approach comes with a steep early learning curve but can reduce initial equipment spend by over 10-fold and will allow for more efficient systems integration during product development.
Marrying these technologies with biochemical or cellular assays has the potential to bring disruptive change across fields as diverse as personalized medicine, diagnostics and drug screening.
Date: Tuesday, May 23, 2023
Time: 09:00 – 12:00 CET
Room: 304
Presenter: Dr Tudor Petreus, Senior Scientist | CN Bio
Is your in vitro toolbox as cutting edge as your portfolio of drug modalities?
Next-generation therapeutics have become a popular way to improve drug delivery, target what was previously considered “undruggable”, and bring novel medicines to patients swiftly. A recent McKinsey report cites that new drug modalities represent around 21% of pipelines – the fastest growth ever seen in the sector.
In this modern era of drug discovery, has your preclinical assay toolbox kept pace with the differing needs of new modalities versus small molecules? For small molecules, traditional in vitro assays are complemented by in vivo animal models. But, for drugs with human-specific modes of action, there are few non-clinical in vivo models available. As such, safety and efficacy testing this new wave of therapeutics represent a significant workflow challenge.
Organ-on-a-chip (OOC), otherwise known as microphysiological systems (MPS), offer a path forward, delivering clinically translatable data that be used to predict the efficacy, drug disposition and safety of drugs – irrespective of modality.
With primary human cells at their core, these complex multicellular in vitro models recapitulate the physiology and function of human organs, including key immune aspects. They can be linked to simulate processes such as drug absorption and metabolism or to understand interactions between organs, such as inflammation, which drive disease and cause unexpected toxicities.
Date: Wednesday, May 24, 2023
Time: 12:00 – 12:15 CET
Room: Hall 3
Presenter: Dr Atefeh Mobasseri, Field Application Scientist | CN Bio
Our Team at SLAS Europe
Adrian
A seasoned business developer with extensive commercial experience in the life science sector, Adrian Rea joined CN-Bio Innovations as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University.
Atefeh
Dr Atefeh Mobasseri, Field Application Scientist at CN Bio, has an extensive background in tissue engineering and regenerative medicine. Before joining CN Bio, she gained a PhD in Biomedical materials from the University of Manchester and carried out postdoctoral roles at the University of Manchester and Kings College London investigating the interaction, and effect, of 3D scaffolds on cellular behaviour. Since joining CN Bio, she has been supporting their European customers in using CN Bio’s range of PhysioMimixTM systems to generate high content, human-relevant, data.
Parham
Dr Parham Ashrafzadeh is the UK/Nordics Account Manager at CN Bio and is based in London. Parham helps scientists within academia, biotech and pharma sectors to find the best solutions for testing their therapeutics which are more cost-effective, clinically relevant and safer at the drug discovery stage. Parham holds a PhD from Uppsala University in Sweden and completed a collaborative postdoctoral fellowship between four universities around the globe.